Skip to main content

Advertisement

SpringerLink
Log in

Overactive Bladder and Outlet Obstruction in Men

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Lower urinary tract symptoms (LUTS), overactive bladder, (OAB), and benign prostatic hyperplasia (BPH) are very commonly experienced in men. The mainstay of pharmacotherapy for OAB is the antimuscarinic class of drugs. There has been reluctance to prescribe these agents to men with BPH due to the risk of precipitating urinary retention. Several trials have supported the efficacy and safety of antimuscarinics in treating men with LUTS, alone, or in combination with α-blocker therapy. The combination of 5-α-reductase inhibitors with antimuscarinic agents or surgery are other effective treatments for men with BPH and OAB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Abrams P, Cardozo L, Fall M, et al.: The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology 2003, 61:37–49.

    Article  PubMed  Google Scholar 

  2. Jaffe WI, Te AE: Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. Curr Urol Rep 2005, 6:410–418.

    Article  PubMed  Google Scholar 

  3. Irwin DE, Milsom I, Hunskaar S, et al.: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006, 50:1306–1314.

    Article  PubMed  Google Scholar 

  4. Kirby R, Lepor H: Evaluation and non-surgical management of benign prostatic hyperplasia, in Wein A, Kavoussi L, Novick A, et al., Urology, 9th ed. Philadelphia, Saunders Elsevier, 2007

    Google Scholar 

  5. Abdel-Aziz KF, Lemack GE: Overactive bladder in the male patient: bladder, outlet, or both? Curr Urol Rep 2002, 3:445–451.

    Article  PubMed  Google Scholar 

  6. de Groat WC: A neurologic basis for the overactive bladder. Urology 1997, 50(6A Suppl):36–52

    PubMed  Google Scholar 

  7. Drake MJ, Mills IW, Gillespie JI: Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet 2001, 358:401–403.

    Article  CAS  PubMed  Google Scholar 

  8. McGuire E: Neuromuscular dysfunction of the lower urinary tract in Walsh P, Gittes R, Perlmutter A, Stamey T: Campbell’s Urology. Philadelphia, W. B. Saunders, 1986.

    Google Scholar 

  9. •• Kaplan SA, Roehrborn CG, Rovner ES, et al.: Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006, 296:2319–2328. This is the only placebo-controlled study published on combination therapy with α-blockers and antimuscarinic agents.

    Article  CAS  PubMed  Google Scholar 

  10. Kaplan SA, Walmsley K, Te AE: Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2008, 179:S82–85.

    Article  PubMed  Google Scholar 

  11. •• Abrams P, Kaplan S, De Koning Gans HJ, Millard R: Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006, 175:999–1004. This study is one of the few to investigate the effects of antimuscarinic therapy in patients with urodynamic BOO.

    Article  CAS  PubMed  Google Scholar 

  12. Lee JY, Kim HW, Lee SJ, et al.: Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU International 2004, 94:817–820.

    Article  CAS  PubMed  Google Scholar 

  13. Chapple CR, Roehrborn CG: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006, 49:651–659.

    Article  PubMed  Google Scholar 

  14. Van Venrooij GE, Van Melick HH, Eckhardt MD, Boon TA: Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol 2002, 168:605–609.

    Article  PubMed  Google Scholar 

  15. Mehdizadeh JL, Leach GE: Role of invasive uodynamic testing in benign prostatic hyperplasia and male lower urinary tract symptoms. Urol Clin N Am 2009, 36:431–441.

    Article  Google Scholar 

  16. Seki N, Kai N, Seguchi H, et al.: Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity. Urology 2006, 67:306–310.

    Article  PubMed  Google Scholar 

  17. Machino R, Kakizaki H, Ameda K, et al.: Detrusor instability with equivocal obstruction: a predictor of unfavorable symptomatic outcomes after transurethral prostatectomy. Neurourol Urodyn 2002, 21:444–449.

    Article  PubMed  Google Scholar 

  18. Coyne KS, Sexton CC, Irwin DE, et al.: The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in menand women: results from the EPIC study. BJU International 2008, 101:1388–1395.

    Article  PubMed  Google Scholar 

  19. Sexton CC, Coyne KS, Kopp ZS, et al.: The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009, 103:12–23.

    Article  PubMed  Google Scholar 

  20. AUA Practice Guidelines Committee: AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. J Urol 2003, 170:530–547.

    Article  Google Scholar 

  21. de la Rosette JJ, Alivizatos G, Madersbacher S, et al.: EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001, 40:256–263.

    Article  PubMed  Google Scholar 

  22. Hyman MJ, Groutz A, Blaivas JG: Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001, 166:550–552.

    Article  CAS  PubMed  Google Scholar 

  23. Roehrborn CG: Focus on lower urinary tract symptoms: nomenclature, diagnosis, and treatment options. Rev Urol 2001, 3:139–145.

    CAS  PubMed  Google Scholar 

  24. Ball AJ, Smith PJ: Urodynamic factors in relation to outcome of prostatectomy. Urology 1986, 28:256–258.

    Article  CAS  PubMed  Google Scholar 

  25. van Venrooij GE, van Melick HH, Boon TA: Comparison of ourcomes of transurethral resection of the prostate in urodynamically obstructed versus selected urodynamically unobstructed or equivocal men. Urology 2003, 62:672–676.

    Article  PubMed  Google Scholar 

  26. Gerber GS, Kim JH, Contreras BA, et al.: An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Urology 1996, 47:840–844.

    Article  CAS  PubMed  Google Scholar 

  27. Kirby RS, Roehrborn CG, Boyle P, et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in the treatment of symptomatic benign prostatic hyperplasia: the prospective European doxazosin and combination therapy (PREDICT) trial. Urology 2003, 61:119–126.

    Article  PubMed  Google Scholar 

  28. Lepor H, Williford WO, Barry MJ, et al.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia: Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996, 335:533–539.

    Article  CAS  PubMed  Google Scholar 

  29. McConnell JD, Roehrborn CG, Bautista OM, et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387–2398.

    Article  CAS  PubMed  Google Scholar 

  30. Van Kerrebroeck P, Kreder K, Jonas U, et al.: Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001, 57:414–421.

    Article  PubMed  Google Scholar 

  31. Roehrborn CG, Boyle P, Nickel JC, et al.; ARIA3001 ARIA3002 and ARIA3003 Study Investigators: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002, 60:434–441.

    Article  PubMed  Google Scholar 

  32. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al.: Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized controlled trial. J Urol 2003, 169:2253–2256.

    Article  CAS  PubMed  Google Scholar 

  33. Lee KS, Choo MS, Kim DY, et al.: Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005, 174:1334–1338.

    Article  CAS  PubMed  Google Scholar 

  34. Kaplan SA, Roehrborn CG, Rovner ES, et al.: Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006, 296:2319–2328

    Article  CAS  PubMed  Google Scholar 

  35. Kaplan SA, Roehrborn CG, Chancellor M, et al.: Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the international prostate symptom score. BJU International 2008, 102:1133–1139.

    Article  CAS  PubMed  Google Scholar 

  36. Rovner ES, Kreder K, Sussman DO, et al.: Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 2008, 180:1034–1041.

    Article  CAS  PubMed  Google Scholar 

  37. Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M and Guan Z: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009, 56:534–541.

    Article  CAS  PubMed  Google Scholar 

  38. MacDiarmid SA, Peters KM, Chen A, et al.: Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized double-blind placebo-controlled study. Mayo Clin Proc 2008, 83:1002–1010.

    Article  CAS  PubMed  Google Scholar 

  39. Roehrborn CG, Kaplan SA, Kraus SR, et al.: Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS including OAB. Urology 2008, 72:1061–1067.

    Article  PubMed  Google Scholar 

  40. Roehrborn CG, Kaplan SA, Jones JS, et al.: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effect of prostate size. Eur Urol 2009, 55:472–479.

    Article  CAS  PubMed  Google Scholar 

  41. • Chung DE, Te AE, Staskin DR, Kaplan SA: Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology 2010, 75:1144–1148. This is a good study examining efficacy of combination therapy of an antimuscarinic agent with a 5-α-reductase inhibitor.

    Article  PubMed  Google Scholar 

  42. Cameron A, Clemens J, Latini J, McGuire E, . Combination Drug Therapy Improves Compliance of the Neurogenic Bladder. J Urol 2009;182(3):1062–7.

    Article  PubMed  Google Scholar 

  43. Amend B, Hennenlotter J, Schafer T, Horstmann M, Stenzl A, Sievert K. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008;53(5):1021–8.

    Article  CAS  PubMed  Google Scholar 

  44. Abrams PH, Farrar DJ, Turner-Warwick RT, et al.: The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979, 121:640–642.

    CAS  PubMed  Google Scholar 

  45. de Nunzio C, Franco G, Rocchegian A, et al.: The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol 2003, 169:535–539.

    Article  PubMed  Google Scholar 

  46. Donovan JL, Peters TJ, Neal DE, et al.: A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study. J Urol 2000, 164:65–70.

    Article  CAS  PubMed  Google Scholar 

  47. Housami F, Abrams P: Persistent detrusor overactivity after transurethral resection of the prostate. Curr Urol Rep 2008, 9:284–290.

    Article  PubMed  Google Scholar 

Download references

Disclosures

D. Chung: none. Dr. Jaspreet Sandhu has served as a consultant for American Medical Systems.

Author information

Authors and Affiliations

  1. Section of Urology, Mount Sinai Hospital, University of Chicago, Chicago, IL, 60608, USA

    Doreen E. Chung

  2. Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA

    Jaspreet S. Sandhu

Authors
  1. Doreen E. Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaspreet S. Sandhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jaspreet S. Sandhu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chung, D.E., Sandhu, J.S. Overactive Bladder and Outlet Obstruction in Men. Curr Urol Rep 12, 77–85 (2011). https://doi.org/10.1007/s11934-010-0157-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-010-0157-x

Keywords

Search

Navigation